ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by retiredcopon Dec 03, 2020 9:14am

90 Views

Post# 32025019

While waiting for the serology test ...

Looks like the UK has approved pfizer's covid vaccine for immediate use... the world waits in anticipation for another FDA advisory board to convene... we know for sure what everyone will be discussing for the next week... almost identical scenerio with Biogen and Aducanumab. What will the advisory board say and will it effect the FDA decision and will outside pressures be influencing what FDA finally does.

" The FDA has arranged a meeting of an independent expert panel to evaluate the Pfizer vaccine, which studies suggest is 95% effective, for December 10."

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide